Paradigm Biopharmaceuticals Limited (PBIGF)
OTCMKTS · Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
At close: Feb 10, 2026

PBIGF Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-18.77-58.73-51.91-39.25-34.3
Depreciation & Amortization
0.150.150.150.190.21
Asset Writedown & Restructuring Costs
2.53----
Stock-Based Compensation
0.11.20.943.273.21
Other Operating Activities
-0.110.050.3-0.86-0.31
Change in Accounts Receivable
-0.291.360.361.79-5.05
Change in Accounts Payable
-0.09-9.345.072.12.2
Change in Other Net Operating Assets
0.48-0.63-0.10.54-0.89
Operating Cash Flow
-15.99-65.94-45.19-32.21-34.93
Capital Expenditures
-----0.03
Sale (Purchase) of Intangibles
-----0
Investment in Securities
0.05---0.7
Investing Cash Flow
0.05---0.67
Long-Term Debt Repaid
-0.13-0.1-0.1-0.14-0.12
Total Debt Repaid
-0.13-0.1-0.1-0.14-0.12
Net Debt Issued (Repaid)
-0.13-0.1-0.1-0.14-0.12
Issuance of Common Stock
1630.1266.40.211.12
Other Financing Activities
-0.88-1.84-3.76--
Financing Cash Flow
14.9928.1862.530.071
Foreign Exchange Rate Adjustments
-0.05-0.74-0.690.770.37
Miscellaneous Cash Flow Adjustments
---0-
Net Cash Flow
-1-38.5116.66-31.36-32.89
Free Cash Flow
-15.99-65.94-45.19-32.21-34.96
Free Cash Flow Margin
----40650.90%-170122.95%
Free Cash Flow Per Share
-0.05-0.23-0.18-0.14-0.15
Cash Interest Paid
0.010.010.020.030.04
Cash Income Tax Paid
-6.3-7.33-7.4-9.53-3.37
Levered Free Cash Flow
-14.29-49.02-31.18-22.04-27.37
Unlevered Free Cash Flow
-14.29-49.01-31.17-22.02-27.34
Change in Working Capital
0.1-8.615.334.44-3.74
Source: S&P Global Market Intelligence. Standard template. Financial Sources.